Immunostaining, using a mouse monoclonal antibody VE1, specific for the most prevalent mutation in thyroid cancer BRAF V600E, has shown excellent concordance with molecular testing (Figure 5a) [153,154,155]. This evidence concerns the gene BRAF and thyroid gland carcinoma.